Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2009 1
2010 1
2011 2
2013 1
2016 1
2017 2
2018 6
2019 4
2020 6
2021 1
2022 3
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Litton JK, et al. Among authors: mina la. N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15. N Engl J Med. 2018. PMID: 30110579 Free PMC article. Clinical Trial.
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F. Menezes MCS, et al. Among authors: mina l. Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332. Cancers (Basel). 2022. PMID: 36077867 Free PMC article. Review.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Litton JK, et al. Among authors: mina la. Oncologist. 2023 Oct 3;28(10):845-855. doi: 10.1093/oncolo/oyad139. Oncologist. 2023. PMID: 37318349 Free PMC article. Clinical Trial.
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Hopkins JF, Albacker LA, Chelliserry J, Chen Y, Conte U, Wardley AM, Robson ME. Turner NC, et al. Among authors: mina la. NPJ Breast Cancer. 2023 Oct 6;9(1):81. doi: 10.1038/s41523-023-00561-y. NPJ Breast Cancer. 2023. PMID: 37803017 Free PMC article.
Patient-Reported Testing Burden of Screening Contrast-Enhanced Mammography.
Patel BK, Gurudu R, Mazza G, Sharpe RE Jr, Mina L, Fraker J, Kling JM, Anderson K, Hughes D, Pockaj B. Patel BK, et al. Among authors: mina l. J Am Coll Radiol. 2024 May;21(5):789-794. doi: 10.1016/j.jacr.2023.11.009. Epub 2023 Nov 11. J Am Coll Radiol. 2024. PMID: 37956885 No abstract available.
35 results